IRGD-CPT

IRGD-CPT is a conjugate of iRGD and camptothecin that is covalently coupled through a heterobifunctional linker. iRGD-CPT has anticancer activity in vitroandin vivo. iRGD-CPT can be used for the study of colon cancer[1].

Product Specifications

UNSPSC

12352005

Target

DNA/RNA Synthesis; Integrin; Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/irgd-cpt.html

Solubility

10 mM in DMSO

Smiles

O=C(CC1SC[C@H](NC(C)=O)C(N[C@@H]2C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(NCC(N3CCC[C@H]3C(N[C@H](C(N[C@@H](CSSC2)C(O)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N(CCC(NOCCOCCOCCCC(O[C@]4(CC)C(OCC5=C4C=C6N(CC7=CC8=CC=CC=C8N=C76)C5=O)=O)=O)=O)C1=O

Molecular Formula

C75H100N18O27S3

Molecular Weight

1781.90

References & Citations

[1]Singh, Tejinder et al. Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy. European journal of medicinal chemistry, vol. 265 116050. 16 Dec. 2023